Indication

Epstein-Barr virus (EBV) Positive Mucocutaneous Ulcer

1 clinical trial

2 drugs

Clinical trial

A Randomized Phase 2 Study of CDX-1127 (Varlilumab) in Combination With Nivolumab in Patients With Relapsed or Refractory Aggressive B-cell Lymphomas

Status: Active (not recruiting), Estimated PCD: 2023-05-26

Drug

Drug